摘要
目的 分析2021~2023年广东药科大学附属第一医院第二类精神药品的使用情况,为促进临床合理使用第二类精神药品提供依据。方法 采用回顾性分析的方法,整理2021~2023年广东药科大学附属第一医院第二类精神药品的基本信息、销售金额、用药频度(DDDs)、限定日费用(DDDc)、药品排序比(B/A)并进行分析。结果 2021~2023年第二类精神药品的销售金额和DDDs逐年上升。DDDc维持在相对稳定的水平。只有酒石酸唑吡坦片、酒石酸布托啡诺注射液、喷他佐辛注射液、咪达唑仑注射液、丁丙诺啡透皮贴剂和盐酸曲马多注射液B/A小于1,其余B/A均≥1。结论 2021~2023年广东药科大学附属第一医院第二类精神药品使用基本合理,建议加强监管,确保临床用药安全、合理。
Objective To analyze the use of classⅡpsychotropic drugs in the First Affiliated Hospital of Guangdong Pharmaceutical University from 2021 to 2023,and provide evidences for rational drug use of classⅡpsychotropic drugs in clinical practice.Methods By retrospective analysis,the information of classⅡpsychotropic drugs from 2021 to 2023 in the First Affiliated Hospital of Guangdong Pharmaceutical University was collected and analyzed,such as general Information,sales amount,defined daily dose system(DDDs),defined daily cost(DDDc),sequence ratio(B/A).Results The consumption sum and DDDs of classⅡpsychotropic drugs in the First Affiliated Hospital of Guangdong Pharmaceutical University increased year by year.The DDDc value of classⅡpsychotropic drugs was generally stable.The B/A of classⅡpsychotropic drugs was greater than or equal to 1 except Zolpidem Tartrate Tablets,Butorphanol Tartrate Injection,Pentazocine Injection,Midazolam Injection,Buprenorphine Transdermal Patch and Tramadol Hydrochloride Injection.Conclusion The use of classⅡpsychotropic drugs in the First Affiliated Hospital of Guangdong Pharmaceutical University is basically reasonable.It is necessary to strengthen the management and monitoring of classⅡpsychotropic drugs to ensure the safety and rationality of clinical medication.
作者
叶嘉俊
叶煜冰
陈永
YE Jiajun;YE Yubing;CHEN Yong(Key Specialty of Clinical Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510080,China)
出处
《中国处方药》
2024年第11期63-66,共4页
Journal of China Prescription Drug
基金
2021年中央财政医疗服务与保障能力提升补助资金资助项目(Z155080000004)。
